Anything less is not real obesity care, and the clinic should not be charging or billing for it
As there is no meaningful expression of GLP-1 receptors on hepatocytes, the major effect of GLP-1 agonists on MASH is likely to be indirect and may be related to a reduction in calorie intake, body weight and insulin resistance, all of which would lead to reduced liver lipid accumulation and hepatic inflammation 7,8
In practice, these effects tend to balance out rather than cause problems
Rybelsus is an oral semaglutide tablet, while Ozempic and Wegovy are injectable semaglutide medications
In fact, both peptides are likely to shuttle glucose and fatty acids into muscle tissue for energy, encouraging muscle growth [14, 15]